Latest Ratios: P/E Ratio -3.9x · EV/EBITDA N/A · ROE -240.1%. (2011–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $19M | $8M | $4M | $8M | $18M | $66M | $36M | $41M | $34M | $19M | $21M |
| Enterprise Value | $11M | $-15691 | $9M | $4M | $14M | $63M | $31M | $36M | $26M | $10M | $17M |
| P/E Ratio → | -3.91 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.85 | 0.82 | 0.68 | 3.36 | 10.94 | 2858.21 | — | — | — | — | — |
| P/B Ratio | 2.98 | 1.20 | — | 2.06 | 4.98 | — | 8.25 | 10.23 | 15.55 | 4.98 | 6.18 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | -0.00 | 1.69 | 1.48 | 8.39 | 2735.57 | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 96.5% | 96.5% | 96.1% | 85.2% | 79.7% | -276.7% | — | — | — | — | — |
| Operating Margin | -50.8% | -50.8% | -143.4% | -310.4% | -503.8% | -56678.3% | — | — | — | — | — |
| Net Profit Margin | -52.2% | -52.2% | -150.4% | -327.8% | -527.7% | -57144.5% | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -240.1% | -240.1% | -1035.4% | -215.3% | -5015.4% | -2256.5% | -169.5% | -244.4% | -410.8% | -296.4% | -191.6% |
| ROA | -43.5% | -43.5% | -82.4% | -73.3% | -85.3% | -166.2% | -118.2% | -111.3% | -141.9% | -114.2% | -97.6% |
| ROIC | -608.5% | -608.5% | -543.4% | — | — | — | — | — | — | — | — |
| ROCE | -228.3% | -228.3% | -195.1% | -80.4% | -147.3% | -415.6% | -170.2% | -162.0% | -163.4% | -135.4% | -111.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.73 | 0.73 | — | 1.26 | 1.41 | — | 0.03 | — | — | — | 1.26 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.20 | — | -1.15 | -1.16 | — | -1.26 | -1.32 | -3.55 | -2.38 | -1.24 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -10.38 | -10.38 | -14.86 | -15.57 | -16.30 | -115.47 | — | -526.83 | -1722.76 | -39.34 | — |
Net cash position: cash ($14M) exceeds total debt ($5M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.66 | 1.66 | 0.71 | 7.08 | 7.51 | 1.23 | 3.10 | 3.46 | 3.82 | 6.58 | 5.19 |
| Quick Ratio | 1.62 | 1.62 | 0.66 | 6.91 | 7.38 | 1.20 | 3.10 | 3.46 | 3.82 | 6.58 | 5.19 |
| Cash Ratio | 1.31 | 1.31 | 0.49 | 5.95 | 6.51 | 1.07 | 2.81 | 3.25 | 3.70 | 6.38 | 4.74 |
| Asset Turnover | — | 0.59 | 0.73 | 0.21 | 0.15 | 0.00 | — | — | — | — | — |
| Inventory Turnover | 0.80 | 0.80 | 0.42 | 1.28 | 1.77 | 0.37 | — | — | — | — | — |
| Days Sales Outstanding | — | 86.19 | 47.42 | 90.91 | 66.59 | 369.61 | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $278558 | $261968 | $223512 | $177028 | $154833 | $115294 | $103457 | $64847 | $45040 |
Liquidity and dilution risk
According to recent market data, EVOK trades at a price-to-sales ratio of 1.85, which suggests that investors are pricing the company as a high-growth commercial entity rather than a traditional value stock, despite the absence of positive earnings or a meaningful dividend yield for shareholders.
The current P/S multiple reflects a market expectation that the Gimoti launch will achieve significant market penetration in the near term. Investors should monitor whether this valuation remains supported as the company continues to navigate its negative earnings trajectory and potential future equity dilution.
Based on reported figures, the company's cash conversion cycle remains deeply negative, with a DSO of 272 days as of 2025Q3, indicating that the firm faces significant challenges in converting its commercial sales into actual cash inflows within a reasonable timeframe for its industry.
The extremely high DIO and DPO figures suggest that inventory management and supplier payment terms are currently inefficient, likely due to the complexities of the Eversana partnership. This lack of working capital velocity warrants further investigation into whether these metrics will normalize as the product launch matures.
As reported in financial statements, the debt-to-equity ratio has climbed to 1.52 in 2025Q3, signaling that the company is increasingly reliant on debt financing to bridge its operational funding gap as its equity base continues to contract due to persistent net losses.
The negative interest coverage ratio of -9.03 highlights the precarious nature of the company's debt service capacity. Investors should be cautious, as the current leverage profile leaves little room for error should the commercial ramp-up of Gimoti fail to meet management's internal projections.
As evidenced by the company's negative TTM P/E of -3.91, the use of traditional earnings-based valuation metrics is fundamentally inappropriate for EVOK, as it obscures the company's true value drivers which are rooted in prescription growth and market share capture rather than current bottom-line profitability.
Analysts should instead focus on EV/Sales or metrics related to prescription volume, such as TRx and NBRx, to assess the company's progress. Relying on P/E ratios in this context may lead to erroneous conclusions regarding the firm's viability and its potential for long-term value creation.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EVOK stock.
Evoke Pharma, Inc.'s current P/E ratio is -3.9x. This places it at the 50th percentile of its historical range.
Evoke Pharma, Inc.'s return on equity (ROE) is -240.1%. The historical average is -247.5%.
Based on historical data, Evoke Pharma, Inc. is trading at a P/E of -3.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Evoke Pharma, Inc. has 96.5% gross margin and -50.8% operating margin.